By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199




GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

Company News
Medivir (MVRBF) Release: Update On The Development Of Simeprevir As Part Of The Triple Combination With AL-335 And Odalasvir (JNJ-4178) 4/24/2017 7:54:52 AM
Medivir (MVRBF) Announces Positive Data From The Phase II Study Of Remetinostat In Patients With Early-Stage Cutaneous T-Cell Lymphoma 4/7/2017 6:27:24 AM
Annual Report 2016 - Medivir (MVRBF) 4/6/2017 9:24:12 AM
Notice Of Annual General Meeting Of Medivir (MVRBF) 4/3/2017 12:07:48 PM
Number Of Shares And Votes In Medivir (MVRBF) 3/31/2017 8:26:34 AM
Medivir (MVRBF) Completes Transition Of Commercial Products To Fully Focus On Research And Development 3/16/2017 11:24:43 AM
Medivir (MVRBF)'s Nomination Committee Proposes New Board Of Directors Ahead Of 2017 AGM 2/24/2017 7:36:46 AM
Executive Management Team Members Increase Their Holdings In Medivir (MVRBF) 2/17/2017 10:46:00 AM
Christine Lind New CEO Of Medivir (MVRBF) Effective 1 April 2017 2/9/2017 7:00:08 AM
Medivir (MVRBF) Release: MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review Of Safety Data Enables Trial Continuation Without Any Modifications 2/1/2017 8:58:50 AM